Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2022-09-19 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics annonce la présentation des résultats de son étude de phase III FRESH, dans l'HTA difficile à traiter/résistante, le 4 Novembre 2022 au congrès annuel de l'American Heart Association
Regulatory Filings Classification · 95% confidence The document is a press release from Quantum Genomics announcing the presentation of Phase III clinical trial results (FRESH study) at the American Heart Association (AHA) annual congress. It details the timing, location, and significance of this data presentation, which is a key step towards regulatory filing. This type of announcement, focusing on clinical trial updates and upcoming presentations at scientific conferences, is typically classified as a general regulatory or corporate announcement, rather than a full financial report (10-K, IR) or a specific management/board change. Since it is an announcement about a significant corporate/scientific event that doesn't fit the specific categories like ER, DIV, or MANG, and it is not a formal regulatory filing form, the most appropriate classification is Regulatory Filings (RNS) as a general corporate disclosure, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the context of clinical trial updates and scientific conference presentations, RNS serves as the best fit for a general, non-financial, non-governance corporate disclosure.
2022-09-19 French
Bilan au 30 juin 2022 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
Transaction in Own Shares Classification · 95% confidence The document is titled "Bilan au 30 juin 2022 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Balance sheet as of June 30, 2022, for the liquidity contract with Gilbert Dupont Stock Brokerage Firm). It details the status of a liquidity contract (market making agreement) for the company Quantum Genomics, showing the number of shares and cash balance as of June 30, 2022, and transaction volumes for the second half of 2021. This type of report, detailing the activity under a specific financial arrangement (liquidity contract/market making), is a specialized financial disclosure. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It relates to the company's financial structure and market operations. Given the specific nature of reporting on liquidity contracts, which often falls under regulatory requirements for market participants or listed companies regarding market stability, the most fitting category among the provided options is 'Capital/Financing Update' (CAP) as it deals directly with the capital structure management via a third party, or potentially 'Regulatory Filings' (RNS) if it's a mandatory periodic disclosure not covered elsewhere. However, since it is a detailed balance sheet/activity report for a specific financial instrument (liquidity contract), and not a general financing announcement (like issuing new shares), it is closest to a specialized financial disclosure. In the context of French market reporting, these liquidity contract reports are often filed periodically. Since there isn't a specific 'Liquidity Contract Report' code, and it details financial activity related to share management, 'CAP' (Capital/Financing Update) is a reasonable fit, although 'RNS' (Regulatory Filings) is a strong fallback. Given the detailed financial tables and the specific date (June 30, 2022), it functions as a periodic financial status update related to share management. I will classify this as a specialized financial report that doesn't fit the main categories, leaning towards RNS as the best fit for non-standard periodic disclosures, or CAP if interpreted as capital management. Given the focus on share inventory and cash related to market making, CAP seems slightly more relevant than the general RNS fallback, but let's re-evaluate. Liquidity contracts are often disclosed under general regulatory announcements. Since it is a detailed report, not just an announcement of a report, I will select RNS as the most appropriate catch-all for specialized, periodic regulatory disclosures not explicitly defined.
2022-07-04 French
Quantum Genomics announces the appointment of its new Scientific Advisory Board
Board/Management Information Classification · 98% confidence The document is an announcement titled "Quantum Genomics announces the appointment of its new Scientific Advisory Board." It details the addition of new members to the board and provides biographies of the appointed experts. This content directly relates to changes in the company's governance structure and key personnel advising on strategy, which aligns best with the Board/Management Information category (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS).
2022-06-27 English
Quantum Genomics annonce la refondation de son comité Scientifique et Clinique
Board/Management Information Classification · 95% confidence The document is a press release from Quantum Genomics announcing the restructuring and appointment of new members to its Scientific and Clinical Committee. This type of announcement details changes in key advisory or governance bodies within the company, specifically focusing on senior experts joining a committee to advise on clinical development and registration strategies. This aligns best with the 'Board/Management Information' category, which covers changes in the company's board or senior management/advisory structures, rather than a formal regulatory filing like 10-K, an earnings release, or a general regulatory announcement (RNS).
2022-06-27 French
Universal Registration Document 2021
Annual Report Classification · 100% confidence The document is a 'Universal Registration Document' (URD) for Quantum Genomics S.A. for the year 2021. In European regulatory contexts, a Universal Registration Document serves as the equivalent of an Annual Report (10-K equivalent), providing comprehensive financial statements, risk factors, management discussion, and corporate governance information. It is a full-length annual disclosure document, not an announcement or a summary. FY 2021
2022-06-13 English
Quantum Genomics annonce la fin du recrutement des patients de l'étude pivot de Phase III, FRESH
Regulatory Filings Classification · 100% confidence The document is a press release from Quantum Genomics announcing the completion of patient recruitment for its Phase III clinical trial (FRESH) for firibastat. It details the study progress, expected results timeline (October 2022), and future regulatory filing plans (Q3 2023). This type of announcement, focusing on operational milestones and clinical trial updates rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general corporate news or regulatory updates. Since it is an announcement about a significant corporate/clinical event and does not fit the specific definitions for ER, IR, CAP, or LTR, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the format, RNS serves as the most appropriate general announcement category for non-standard filings.
2022-05-09 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.